CPSE:NOVO BPharmaceuticals
Does EU Approval Of Oral Wegovy Pill Reshape The Bull Case For Novo Nordisk (CPSE:NOVO B)?
Earlier this week, the European Commission granted marketing authorisation for Novo Nordisk’s once‑daily oral Wegovy semaglutide 25 mg pill and a new 7.2 mg Wegovy injection pen for adult obesity and overweight across all EU member states, as an adjunct to diet and physical activity.
This makes Wegovy the first GLP‑1 receptor agonist available in tablet form for obesity in Europe, potentially reshaping patient preferences and competitive dynamics in the region’s weight‑management...